ES009: Potential Best-in-Class Monoclonal Antibody Targeting LILRB2
ES009 is a potential best-in-class monoclonal antibody targeting LILRB2 designed to reprogram inhibitory myeloid cells to create an immune favorable tumor microenvironment (TME).
LILRB2 is a critical inhibitory receptor expressed on myeloid cells (including monocytes, dendritic cells, macrophages and neutrophils), mediated by functional ligands such as HLA-G which are mainly expressed on tumor cells. LILRB2-mediated immune suppression is regarded as one mechanism of anti-PD-(L)1 resistance.